

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001624422			X Corporation
Name of Issuer			Limited Partnership
Erytech Pharma			Limited Liability Company
Jurisdiction of Incorporation/Organization			General Partnership
FRANCE			Business Trust
Year of Incorporation/Organization			Other (Specify)
X Over Five Years Ago			
Within Last Five Years (Specify Year)			
Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Erytech Pharma	60 AVENUE ROCKEFELLER		LYON	FRANCE	69008	011-33-4-78-74-44-38

3. Related Persons

Last Name	First Name	Middle Name	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode
BEYEN	Gil		3 Place des Celestins		LYON	FRANCE	69002
Relationship: X Executive Officer X Director Promoter							

Clarification of Response (if Necessary):

Chairman and Chief Executive Officer

Last Name	First Name	Middle Name	Street Address 1	Street Address 2	City	State/Province/Country	ZIP/PostalCode
GOINEAU	Pierre-Olivier		7 Rue Sala		LYON	FRANCE	69002
Relationship: X Executive Officer X Director X Promoter							

Clarification of Response (if Necessary):

Chief Operating Officer

Last Name	First Name	Middle Name
GODFRIN	Yann	
Street Address 1	Street Address 2	
23 Rue Henri Gorjus		
City	State/Province/Country	ZIP/PostalCode
LYON	FRANCE	69005

Relationship: X Executive Officer X Director X Promoter

Clarification of Response (if Necessary):

Chief Scientific Officer

Last Name	First Name	Middle Name
BAILLY	Jerome	
Street Address 1	Street Address 2	
5 Rue Benoit Berlioz		
City	State/Province/Country	ZIP/PostalCode
CHASSIEU	FRANCE	69680

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Qualified Person

Last Name	First Name	Middle Name
GALENOS	None	
Street Address 1	Street Address 2	
25 Rue Jean-Baptiste MEUNIER		
City	State/Province/Country	ZIP/PostalCode
IXELLES	BELGIUM	1050

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
ARCHINARD	Philippe	
Street Address 1	Street Address 2	
47 Rue du Pr Deperet		
City	State/Province/Country	ZIP/PostalCode
TASSIN-LA-DEMI-LUNE	FRANCE	69160

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
WINDELS	Hilde	
Street Address 1	Street Address 2	
Rollebaan 85		
City	State/Province/Country	ZIP/PostalCode
MOORTSELE	BELGIUM	9860

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name**First Name****Middle Name**

GEORGE

Martine

Street Address 1**Street Address 2**

9 Southern Hills Drive

City**State/Province/Country****ZIP/PostalCode**

SKILLMAN

NEW JERSEY

NJ08558

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Health Care

Retailing

Banking & Financial Services

X Biotechnology

Restaurants

Commercial Banking

Health Insurance

Technology

Insurance

Hospitals & Physicians

Computers

Investing

Pharmaceuticals

Telecommunications

Investment Banking

Other Health Care

Other Technology

Pooled Investment Fund

Manufacturing

Travel

Is the issuer registered as an investment company under the Investment Company Act of 1940?

Real Estate

Airlines & Airports

Yes

No

Commercial

Lodging & Conventions

Other Banking & Financial Services

Construction

Tourism & Travel Services

Business Services

REITS & Finance

Other Travel

Energy

Residential

Other

Coal Mining

Other Real Estate

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range**OR****Aggregate Net Asset Value Range**

No Revenues

No Aggregate Net Asset Value

\$1 - \$1,000,000

\$1 - \$5,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

\$5,000,001 - \$25,000,000

\$25,000,001 - \$50,000,000

\$25,000,001 - \$100,000,000

\$50,000,001 - \$100,000,000

Over \$100,000,000

Over \$100,000,000

X Decline to Disclose

Decline to Disclose

Not Applicable

Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i)

Section 3(c)(1)

Section 3(c)(9)

Rule 504 (b)(1)(ii)

Section 3(c)(2)

Section 3(c)(10)

Rule 504 (b)(1)(iii)

Section 3(c)(3)

Section 3(c)(11)

Rule 505

X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing

New Notice Date of First Sale 2014-10-24 First Sale Yet to Occur
 X Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number X None	
BRYAN GARNIER & CO	None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	
Street Address 1	Street Address 2	
53 Chandos Place		
City	State/Province/Country	ZIP/Postal Code
LONDON	UNITED KINGDOM	WC2N 4HS
State(s) of Solicitation (select all that apply)	X All States	X Foreign/non-US
Check "All States" or check individual States		

Recipient	Recipient CRD Number	None
LifeSci Capital	168404	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	
Street Address 1	Street Address 2	
250 West 55th Street	Suite 16B	
City	State/Province/Country	ZIP/Postal Code

State(s) of Solicitation (select all that apply)

Check All States or check individual States

X All States

Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount USD or X Indefinite

Total Amount Sold \$37,232,686 USD

Total Remaining to be Sold USD or X Indefinite

Clarification of Response (if Necessary):

The total amount sold in the USA under exemption and in Europe is exactly of a total of 29,999,980.50 euros

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

33

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$1,781,648 USD Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

The exact amount is 1,434,999 euros

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment

Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Erytech Pharma	Gil BEYEN	Gil BEYEN	Chief Executive Officer	2014-11-10

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
